XML 51 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Operating activities      
Net loss $ (85,779) $ (59,504) $ (14,943)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation 5,679 4,470 5,084
Amortization of premium on investments 2,997 658 841
Loss (gain) on disposal of property and equipment 98 (10) (1)
Stock-based compensation 27,681 18,698 3,444
Realized gain on sales of available-for-sale securities (203) 0 (301)
Changes in operating assets and liabilities:      
Accounts receivable ($578, $979 and $2,772 from related party) (1,952) 4,041 (8,711)
Prepaid expenses and other current assets 978 (1,628) 791
Other assets (420) (795) (547)
Accounts payable 1,970 3,485 (2,041)
Accrued liabilities ($(2,549), $1,828 and $1,644 from related party) (2,126) 18,878 11,307
Deferred revenue 27,654 33,557 30,885
Lease financing liability 627 814 690
Other long-term liabilities 4,225 (250) (580)
Net cash provided by (used in) operating activities (18,571) 22,414 25,918
Investing activities      
Purchases of property and equipment (1,977) (8,118) (6,806)
Proceeds from sale of property and equipment 2 10 2
Purchases of available-for-sale securities (41,736) (144,727) 0
Proceeds from sales of available-for-sale securities 15,342 0 16,582
Proceeds from maturities of available-for-sale securities 22,501 45,546 1,000
Net cash provided by (used in) investing activities (5,868) (107,289) 10,778
Financing activities      
Borrowings under credit facility 0 0 11,500
Repayments under credit facility 0 0 (11,500)
Repayments of capital lease obligations 0 0 (329)
Repayments of lease liability (403) (403) (403)
Proceeds from lease financing liability 0 0 553
Proceeds from convertible promissory note 0 0 600
Proceeds from non-controlling interest 0 0 175
Proceeds from initial public offering, net of underwriting discounts and commission costs 0 155,933 0
Proceeds from AstraZeneca private placement 0 20,000 0
Proceeds from issuance of common stock, net 12,749 1,697 84
Payments of deferred offering costs 0 (3,135) 0
Net cash provided by financing activities 12,346 174,092 680
Effect of exchange rate change on cash and cash equivalents (38) (94) 84
Net increase (decrease) in cash and cash equivalents (12,131) 89,123 37,460
Cash and cash equivalents at beginning of period 165,455 76,332 38,872
Cash and cash equivalents at end of period 153,324 165,455 76,332
Supplemental cash flow information:      
Interest payments 335 377 433
Purchases of property and equipment in accounts payable and accrued liabilities 931 280 1,655
Assets acquired under facility lease 0 0 3,067
Deferred offering costs recorded in accounts payable and accrued liabilities $ 0 $ 974 $ 0